EXAS - Exact Sciences Corp Stock Price, Fair Value and News

$101.31+0.11 (+0.11%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

EXAS Price Action

Last 7 days

-0.1%

Last 30 days

51.2%

Last 90 days

97.1%

Trailing 12 Months

67.3%

EXAS RSI Chart

EXAS Valuation

Market Cap

19.2B

Price/Earnings (Trailing)

-19.46

Price/Sales (Trailing)

6.23

EV/EBITDA

-22.61

Price/Free Cashflow

77.69

EXAS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

EXAS Fundamentals

EXAS Revenue

Revenue (TTM)

3.1B

Rev. Growth (Yr)

20.05%

Rev. Growth (Qtr)

4.89%

EXAS Earnings

Earnings (TTM)

-986.6M

Earnings Growth (Yr)

48.76%

Earnings Growth (Qtr)

-1.6K%

EXAS Profitability

Operating Margin

69.42%

EBT Margin

-32.28%

Return on Equity

-39.44%

Return on Assets

-16.72%

Free Cashflow Yield

1.29%

EXAS Investor Care

Shares Dilution (1Y)

2.37%

Diluted EPS (TTM)

-5.32

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	2.8B	2.9B	3.1B	0
2024	2.5B	2.6B	2.7B	2.8B
2023	2.2B	2.3B	2.4B	2.5B
2022	1.9B	1.9B	2.0B	2.1B
2021	1.5B	1.7B	1.8B	1.8B
2020	1.1B	1.1B	1.3B	1.5B
2019	526.2M	623.2M	723.7M	876.3M
2018	307.9M	353.2M	398.9M	454.5M
2017	132.9M	169.4M	213.8M	266.0M
2016	50.0M	63.1M	78.6M	99.4M
2015	5.8M	13.9M	26.5M	39.4M
2014	3.4M	2.4M	1.3M	1.8M
2013	4.1M	4.1M	4.1M	4.1M
2012	4.2M	4.2M	4.2M	4.1M
2011	5.1M	4.8M	4.5M	4.2M
2010	0	0	0	5.3M

Get all data in R, Python etc through our Historical Stock Data APIs

About Exact Sciences Corp

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

CEO	Mr. Kevin T. Conroy
WEBSITE	exactsciences.com
SECTOR	Healthcare
INDUSTRY	Diagnostics & Research
EMPLOYEES	6300

Exact Sciences Corp Frequently Asked Questions

What is the ticker symbol for Exact Sciences Corp? What does EXAS stand for in stocks?

EXAS is the stock ticker symbol of Exact Sciences Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Exact Sciences Corp (EXAS)?

As of Wed Dec 03 2025, market cap of Exact Sciences Corp is 19.2 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of EXAS stock?

You can check EXAS's fair value in chart for subscribers.

Is Exact Sciences Corp a good stock to buy?

The fair value guage provides a quick view whether EXAS is over valued or under valued. Whether Exact Sciences Corp is cheap or expensive depends on the assumptions which impact Exact Sciences Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for EXAS.

What is Exact Sciences Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, EXAS's PE ratio (Price to Earnings) is -19.46 and Price to Sales (PS) ratio is 6.23. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EXAS PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Exact Sciences Corp's stock?

In the past 10 years, Exact Sciences Corp has provided 0.28 (multiply by 100 for percentage) rate of return.